Tag: M&A impact

Scenario Planning: Best-Case and Worst-Case M&A and Licensing Effects on Trials Outlooks Scenario Planning: Best-Case and Worst-Case M&A and Licensing Effects on Trials Outlooks In the fast-evolving landscape of clinical research, mergers and acquisitions (M&A) and licensing agreements are pivotal in shaping the future of pharmaceutical development. These strategic decisions can substantially affect the trajectory…

Read More “Scenario Planning: Best-Case and Worst-Case M&A and Licensing Effects on Trials Outlooks” »

KPIs, Dashboards and Scorecards to Track M&A and Licensing Effects on Trials KPIs, Dashboards and Scorecards to Track M&A and Licensing Effects on Trials In the evolving landscape of pharmaceutical clinical trials, understanding the impact of mergers and acquisitions (M&A) and licensing agreements is critical for stakeholders. This guide is designed to provide clinical operations,…

Read More “KPIs, Dashboards and Scorecards to Track M&A and Licensing Effects on Trials” »

Vendor, Site and Partner Negotiation Tactics Driven by M&A and Licensing Effects on Trials Vendor, Site and Partner Negotiation Tactics Driven by M&A and Licensing Effects on Trials The global landscape of clinical trials is ever-changing, compelling clinical operations, regulatory affairs, and medical affairs professionals to develop robust negotiation tactics when dealing with vendors, sites,…

Read More “Vendor, Site and Partner Negotiation Tactics Driven by M&A and Licensing Effects on Trials” »

Investor, Board and C-Suite Questions Around M&A and Licensing Effects on Trials—Answered In the highly dynamic landscape of clinical research, mergers and acquisitions (M&A), along with licensing agreements, can significantly impact the course of pharma clinical trials. Understanding their implications is essential for stakeholders across clinical operations, regulatory affairs, and medical affairs. This guide provides…

Read More “Investor, Board and C-Suite Questions Around M&A and Licensing Effects on Trials—Answered” »

Future Trends: AI, RWE and New Business Models in M&A and Licensing Effects on Trials The landscape of clinical research is rapidly evolving, influenced by technological advancements, novel regulatory frameworks, and innovative business models. As we delve into the future of clinical trials, it is vital that clinical operations, regulatory affairs, and medical affairs professionals…

Read More “Future Trends: AI, RWE and New Business Models in M&A and Licensing Effects on Trials” »

Digital Tools and Analytics to Forecast and Monitor M&A and Licensing Effects on Trials The landscape of clinical trials is continually evolving, particularly in the context of mergers and acquisitions (M&A) and licensing agreements that significantly impact how clinical research is conducted. For professionals engaged in clinical operations, regulatory affairs, and medical affairs, understanding the…

Read More “Digital Tools and Analytics to Forecast and Monitor M&A and Licensing Effects on Trials” »

Risk Scenarios and Sensitivity Analyses for M&A and Licensing Effects on Trials Risk Scenarios and Sensitivity Analyses for M&A and Licensing Effects on Trials In the complex landscape of clinical trials, the implications of mergers and acquisitions (M&A) and licensing arrangements are profound. As the biopharmaceutical industry continues to evolve, understanding the risks associated with…

Read More “Risk Scenarios and Sensitivity Analyses for M&A and Licensing Effects on Trials” »

Regulatory and Policy Shifts Reshaping M&A and Licensing Effects on Trials in the US, EU and UK Regulatory and Policy Shifts Reshaping M&A and Licensing Effects on Trials in the US, EU and UK The landscape of clinical trials is continuously evolving, driven by various regulatory and policy shifts. These changes are particularly significant in…

Read More “Regulatory and Policy Shifts Reshaping M&A and Licensing Effects on Trials in the US, EU and UK” »

Using Real-World Data to Inform M&A and Licensing Effects on Trials Decisions Using Real-World Data to Inform M&A and Licensing Effects on Trials Decisions The landscape of clinical research is constantly evolving, particularly in the context of mergers and acquisitions (M&A) and licensing agreements within the pharmaceutical and biotechnology sectors. The use of real-world data…

Read More “Using Real-World Data to Inform M&A and Licensing Effects on Trials Decisions” »

Governance Models and Cross-Functional Ownership for M&A and Licensing Effects on Trials Governance Models and Cross-Functional Ownership for M&A and Licensing Effects on Trials The impact of mergers and acquisitions (M&A) and licensing agreements on clinical trials is significant and multifaceted. As the biopharmaceutical landscape evolves, understanding the governance models and cross-functional ownership that influence…

Read More “Governance Models and Cross-Functional Ownership for M&A and Licensing Effects on Trials” »